

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

îcants:

C.A. Blau et al.

Attorney Docket No.: UWOTL115624

Application No.: 09/582,916

Group Art Unit: 1632

Filed:

October 2, 2000

Examiner: A.M. Beckerleg

Title:

METHODS OF CONTROLLING CELL DIFFERENTIAION

USING A FUSION PROTEIN AND A DRUG

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Seattle, Washington 98101

August 26, 2002

TO THE COMMISSIONER FOR PATENTS:

Applicants are aware of the information listed in the attached form that may be material to the prosecution of the above-identified patent application.

Copies of the other information are enclosed for the Examiner's use. 1. \mathbf{X}

2. X Pursuant to 37 C.F.R. § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the national application (other than a CPA), within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application, before the mailing date of a first Office Action on the merits, or before the mailing date of a first Office Action after the filing of an RCE.

Respectfully submitted,

RECEIVED

CHRISTENSEN O'CONNOR JOHNSON KINDNESSPLLC

SEP 0 3 2002

TECH CENTER 1600/2900

Dennis K. Shelton

Registration No. 26,997 Direct Dial No. 206.695.1718

I hereby certify that this correspondence is being deposited with the U.S. Postal Service in a sealed envelope as first class mail with postage thereon fully prepaid and addressed to the U.S. Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202, on the below date.

august 24, 2002

DKS:cff

UWOTIA15624163

LAW OFFICES OF CHRISTENSEN O'CONNOR JOHNSON KINDNESSPILE 1420 Fifth Avenue **Suite 2800** Seattle, Washington 98101 206.682.8100

FORMATION CITED BY APPLICANTS THAT MAY BE MATERIAL TO THE PROSECUTION OF THE SUBJECT APPLICATION Attorney Docket No. UWOTL115624 Applicant: C.A. Blau et al. Application No.: 09/582,916 Group Art Unit: 1632 October 2, 2000 Filed: Examiner: A.M. Beckerleg METHODS OF CONTROLLING CELL DIFFERENTIATION/USING A Title: FUSION PROTEIN AND A DRUG RECEIVED **U.S. PATENT DOCUMENTS** *Examiner Cite Date Kind SEP 0 3 2002 **Initials** No. Document No. (mm/dd/yyyy) Name Code TECH CENTER 1600/2900 None FOREIGN PATENT DOCUMENTS English *Examiner Cite Publication Date Kinð Abstract Translation Initial Document No. No. Code (mm/dd/vs Country Provided Provided None DUPLICATE OF IDS of 5/23/03 OTHER INFORMATION (Including Author, Title, Date, Pertinent Pages, Etc.) *Examiner Cite Initial No. O5 Kudla, Arthur, et al., "The FGF Receptor Tyrosine Kinase Domain Regulates Myogenesis but Is Not Sufficient to Stimulate Proliferation," The Journal of Cell Biology, 142(1):241-250, 1998.

Date Considered

Science 262:1019-1024, November 12, 1993.

Spencer, David M., "Controlling Signal Transduction With Synthetic Ligands,"

*Examiner Initial if reference considered, whether or not citation is in conformance with M.P.E.P § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESSPLLC
1420 Fifth Avenue, Suite 2800
Seattle, Washington 98101
206.682.8100

Examiner